Abstract
In this month’s edition of Clinical Lymphoma, Myeloma & Leukemia, Zhuang et al provide an insightful review on the affect that polymorphic variants in Fcγ receptors (FcγRs) play in predicting response outcome in patients with non-Hodgkin lymphoma (NHL) who receive rituximab therapy.1 The paper nicely outlines the potential role and limitations of predictive genomics involving FcγR polymorphisms (Figure 1). Since the report by Cartron et al in 2002 showing that polymorphisms in FcγRIIIA-158 were associated with response to rituximab in patients with follicular NHL, a number of interesting queries have arisen on just how polymorphic FcγR testing could be used in the real-world practice of hematologists and oncologists.2 These queries have included:
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
